News

Cell Medica will use the investment capital to continue to progress its three proprietary technology platforms for cell-based immunotherapy products. The Company’s lead oncology product, baltaleucel-T (CMD-003), is

Emflaza is the first treatment approved in the US for all Duchenne muscular dystrophy (DMD) patients five years and older, regardless of their genetic mutation. DMD is a rare

The decision means that eligible adults with severe AD can access dupilumab before the drug is granted marketing authorisation in the UK. Allergy UK CEO Carla Jones said:

The drug, Firdapse, was being tested on seven patients with Musk-MG, a rare subpopulation of MG patients. The seven-patient trial assessed the safety, tolerability and efficacy of Firdapse

The trial established that the drug had significantly improved the progression-free survival (PFS) in ovarian cancer patients with germline BRCA-mutations (gBRCA) whose disease had relapsed, and had also

The commercial license builds on an existing research and clinical licensing agreement for select disease areas. Under the terms of the license, Crispr Therapeutics and Casebia will obtain

Pfizer expects to launch Zavicefta in additional markets outside the U.S. throughout 2017 and 2018. Zavicefta was developed in response to the urgent medical need for new antibiotics

Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, has been approved to treat adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after

The companies will focus on a single G protein-coupled receptor (GPCR) nominated by Daiichi Sankyo that plays a crucial role in relieving pain. Under the terms of the